Caloric restriction mimetics for the treatment of cardiovascular diseases. Issue 6 (24th October 2020)

• Record Type: Journal Article
• Authors: Sciarretta, Sebastiano; Forte, Maurizio; Castoldi, Francesca; Frati, Giacomo; Versaci, Francesco; Sadoshima, Junichi; Kroemer, Guido; Maiuri, Maria Chiara
• Is Part Of: Cardiovascular research. Volume 117:Issue 6(2021)
• Page Start: 1434
• Page End: 1449
• Publication Date: 2020-10-24
• Subjects: Caloric restriction mimetics -- Cardiovascular diseases -- Autophagy -- Cardiac ageing -- Starvation; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvaa297
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Caloric restriction mimetics (CRMs) are emerging as potential therapeutic agents for the treatment of cardiovascular diseases. CRMs include natural and synthetic compounds able to inhibit protein acetyltransferases, to interfere with acetyl coenzyme A biosynthesis, or to activate (de)acetyltransferase proteins. These modifications mimic the effects of caloric restriction, which is associated with the activation of autophagy. Previous evidence demonstrated the ability of CRMs to ameliorate cardiac function and reduce cardiac hypertrophy and maladaptive remodelling in animal models of ageing, mechanical overload, chronic myocardial ischaemia, and in genetic and metabolic cardiomyopathies. In addition, CRMs were found to reduce acute ischaemia–reperfusion injury. In many cases, these beneficial effects of CRMs appeared to be mediated by autophagy activation. In the present review, we discuss the relevant literature about the role of different CRMs in animal models of cardiac diseases, emphasizing the molecular mechanisms underlying the beneficial effects of these compounds and their potential future clinical application.